313 related articles for article (PubMed ID: 9622067)
1. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors.
Lu KH; Bell DA; Welch WR; Berkowitz RS; Mok SC
Cancer Res; 1998 Jun; 58(11):2328-30. PubMed ID: 9622067
[TBL] [Abstract][Full Text] [Related]
2. Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions.
Emerson RE; Wang M; Liu F; Lawrence WD; Abdul-Karim FW; Cheng L
Int J Gynecol Pathol; 2007 Oct; 26(4):387-94. PubMed ID: 17885488
[TBL] [Abstract][Full Text] [Related]
3. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
[TBL] [Abstract][Full Text] [Related]
4. X chromosome inactivation and microsatellite instability in early and advanced bilateral ovarian carcinomas.
Park TW; Felix JC; Wright TC
Cancer Res; 1995 Nov; 55(21):4793-6. PubMed ID: 7585507
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas.
Jones TD; Eble JN; Wang M; MacLennan GT; Delahunt B; Brunelli M; Martignoni G; Lopez-Beltran A; Bonsib SM; Ulbright TM; Zhang S; Nigro K; Cheng L
Clin Cancer Res; 2005 Oct; 11(20):7226-33. PubMed ID: 16243792
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas.
Tsao SW; Mok CH; Knapp RC; Oike K; Muto MG; Welch WR; Goodman HM; Sheets EE; Berkowitz RS; Lau CC
Gynecol Oncol; 1993 Jan; 48(1):5-10. PubMed ID: 8423021
[TBL] [Abstract][Full Text] [Related]
7. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas.
Dodson MK; Hartmann LC; Cliby WA; DeLacey KA; Keeney GL; Ritland SR; Su JQ; Podratz KC; Jenkins RB
Cancer Res; 1993 Oct; 53(19):4456-60. PubMed ID: 8402612
[TBL] [Abstract][Full Text] [Related]
8. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
9. Advanced ovarian carcinoma: molecular evidence of unifocal origin.
Li S; Han H; Resnik E; Carcangiu ML; Schwartz PE; Yang-Feng TL
Gynecol Oncol; 1993 Oct; 51(1):21-5. PubMed ID: 8244169
[TBL] [Abstract][Full Text] [Related]
10. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
11. A one centimorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive epithelial ovarian tumors.
Edelson MI; Lau CC; Colitti CV; Welch WR; Bell DA; Berkowitz RS; Mok SC
Oncogene; 1998 Jan; 16(2):197-202. PubMed ID: 9464537
[TBL] [Abstract][Full Text] [Related]
12. Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease.
Kupryjanczyk J; Thor AD; Beauchamp R; Poremba C; Scully RE; Yandell DW
Mod Pathol; 1996 Mar; 9(3):166-73. PubMed ID: 8685209
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas.
Choi C; Cho S; Horikawa I; Berchuck A; Wang N; Cedrone E; Jhung SW; Lee JB; Kerr J; Chenevix-Trench G; Kim S; Barrett JC; Koi M
Genes Chromosomes Cancer; 1997 Nov; 20(3):234-42. PubMed ID: 9365830
[TBL] [Abstract][Full Text] [Related]
14. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetic evidence for monoclonal origin of bilateral ovarian serous borderline tumors.
Sieben NL; Kolkman-Uljee SM; Flanagan AM; le Cessie S; Cleton-Jansen AM; Cornelisse CJ; Fleuren GJ
Am J Pathol; 2003 Apr; 162(4):1095-101. PubMed ID: 12651602
[TBL] [Abstract][Full Text] [Related]
16. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
17. Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas.
Osterberg L; Akeson M; Levan K; Partheen K; Zetterqvist BM; Brännström M; Horvath G
Cancer Genet Cytogenet; 2006 Jun; 167(2):103-8. PubMed ID: 16737908
[TBL] [Abstract][Full Text] [Related]
18. Different patterns of allelic loss (loss of heterozygosity) in recurrent human pituitary tumors provide evidence for multiclonal origins.
Clayton RN; Pfeifer M; Atkinson AB; Belchetz P; Wass JA; Kyrodimou E; Vanderpump M; Simpson D; Bicknell J; Farrell WE
Clin Cancer Res; 2000 Oct; 6(10):3973-82. PubMed ID: 11051246
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
20. Borderline malignant serous tumors of the ovary maintained on extracellular matrix: evidence for clonal evolution and invasive potential.
Crickard K; Marinello MJ; Crickard U; Satchidanand SK; Yoonessi M; Caglar H
Cancer Genet Cytogenet; 1986 Oct; 23(2):135-43. PubMed ID: 3756833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]